Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04317287 · ClinicalTrials.gov registry record · NA
To Assess the Efficacy and Safety of the Cardio Formulation in Reducing Oxidized LDL
A NA study, sponsored by Supplement Formulators.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT04317287 is a NA study that was terminated before completion, run by Supplement Formulators. The registered enrollment target is 9 participants.
The verdict
NCT04317287, a NA study, was terminated before completion, sponsored by Supplement Formulators.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of the Cardio formulation in reducing oxidized LDL \[(Ox LDL (low density lipoprotein)\] in overweight to mildly obese generally healthy adults.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Cardio formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2021-11-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04317287
The ClinicalTrials.gov registry entry for NCT04317287 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supplement Formulators, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04317287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04317287 about?
NCT04317287 is a clinical study titled "To Assess the Efficacy and Safety of the Cardio Formulation in Reducing Oxidized LDL". The purpose of this study is to assess the efficacy and safety of the Cardio formulation in reducing oxidized LDL \[(Ox LDL (low density lipoprotein)\] in overweight to mildly obese generally healthy adults.
What is the current status of trial NCT04317287?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2019-12-10. Estimated completion is 2021-11-19.
What interventions are being tested in trial NCT04317287?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Cardio formulation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04317287?
This trial is sponsored by Supplement Formulators, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.